Analysis by Dr. Joseph Mercola Fact Checked February 09, 2023
STORY AT-A-GLANCE
Moderna just moved one step closer to bringing mRNA-1345, an RSV shot, to market
The U.S. Food and Drug Administration granted the experimental shot fast-track
designation in August 2021
Now, Moderna’s mRNA RSV shot has been given Breakthrough Therapy Designation,
which allows for faster development and an expedited review period
RSV is usually not serious; most people experience only mild, cold-like symptoms and
recover on their own in a week or two
Moderna plans to file for FDA approval of mRNA-1345 in the first half of 2023
Along with Moderna’s mRNA RSV shot, Pfizer and GSK have also developed RSV
vaccines that are awaiting regulatory approval